Compare · head to head
Innovent Biologics vs Mesoblast
Innovent Biologics ranks higher overall — 360 rank 68 vs 42.
Innovent Biologics leads on Quality (67 vs 51) and Safety (62 vs 39). Mesoblast leads on Growth (59 vs 49). The two are close on Value and Sentiment.
Ranks as of 2026-06-12 · 1–100 vs true peers. Higher is better.
| Compare | ||
|---|---|---|
| Profile | ||
| Country | China | Australia |
| Sector | Health Care | Health Care |
| Industry | Biotechnology | Biotechnology |
| Size | Large | Small |
| ISIN | KYG4818G1010 | AU000000MSB8 |
| Last update | 2026-04-02 | 2026-04-02 |
| History | ||
| 360 (V1) since 2023 | ||
| Ranks | ||
| 360 | 68 | 42 |
| Value | 40 | 37 |
| Quality | 67 | 51 |
| Growth | 49 | 59 |
| Safety | 62 | 39 |
| Sentiment | 51 | 53 |
| Quality details | ||
| Profitability | 60 | 58 |
| Cash Truth | 74 | 44 |
Innovent Biologics vs Samsung EpisInnovent Biologics vs CelltrionInnovent Biologics vs GC BiopharmaInnovent Biologics vs Clinuvel PharmaceuticalsAdd a third stock →
Full analyses: Innovent Biologics · Mesoblast
Make Sense of the Ranks
Every rank runs 1–100 against true peers. Higher is always better.
360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100